The National Advisory Committee on Immunization (NACI) and the Comité sur l’immunisation du Québec (CIQ) has updated their COVID–19 booster recommendations for patients at high–risk of COVID–19. Although many patients feel that their risk of severe COVID–19 is minimal, there are a large portion of
Canadians who are at significantly elevated risk. This webinar will address the key issues that you will need to know to mitigate severe COVID–19 risk in these vulnerable populations.
This webinar has received funding from Moderna Biopharm Canada Inc